IL103059A0 - Conjugates for introducing nucleic acid into higher eucaryotic cells - Google Patents
Conjugates for introducing nucleic acid into higher eucaryotic cellsInfo
- Publication number
- IL103059A0 IL103059A0 IL103059A IL10305992A IL103059A0 IL 103059 A0 IL103059 A0 IL 103059A0 IL 103059 A IL103059 A IL 103059A IL 10305992 A IL10305992 A IL 10305992A IL 103059 A0 IL103059 A0 IL 103059A0
- Authority
- IL
- Israel
- Prior art keywords
- conjugates
- nucleic acid
- cell
- introducing nucleic
- eucaryotic cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10041—Use of virus, viral particle or viral elements as a vector
- C12N2710/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
- C12N2710/10241—Use of virus, viral particle or viral elements as a vector
- C12N2710/10243—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10211—Aviadenovirus, e.g. fowl adenovirus A
- C12N2710/10251—Methods of production or purification of viral material
Abstract
Conjugates in which a virus is bound via an antibody to a substance with affinity for nucleic acids in order to transport gene constructs into higher eukaryotic cells. Complexes of the conjugates and nucleic acid are, where appropriate with the cooperation of a cell type-specific internalisation factor, internalised into the cell, where the virus, as constituent of the complex, brings about the internalisation as well as the release of the contents of the endosomes in which the complexes are located after entry into the cell. Pharmaceutical compositions in which the nucleic acid is a therapeutically effective gene construct, especially for use in gene therapy, and transfection kits. <IMAGE>
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US76778791A | 1991-09-30 | 1991-09-30 | |
US82704992A | 1992-01-30 | 1992-01-30 | |
US86475892A | 1992-04-07 | 1992-04-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
IL103059A0 true IL103059A0 (en) | 1993-02-21 |
Family
ID=27419640
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL103059A IL103059A0 (en) | 1991-09-30 | 1992-09-04 | Conjugates for introducing nucleic acid into higher eucaryotic cells |
Country Status (15)
Country | Link |
---|---|
EP (2) | EP0535576A1 (en) |
JP (1) | JP3479298B2 (en) |
CN (1) | CN1071457A (en) |
AT (1) | ATE187497T1 (en) |
AU (1) | AU669335B2 (en) |
CA (1) | CA2114800A1 (en) |
DE (1) | DE59209778D1 (en) |
FI (1) | FI941473A0 (en) |
HU (2) | HUT71322A (en) |
IL (1) | IL103059A0 (en) |
MX (1) | MX9205226A (en) |
NO (1) | NO941155D0 (en) |
NZ (1) | NZ244291A (en) |
TW (1) | TW249247B (en) |
WO (1) | WO1993007282A1 (en) |
Families Citing this family (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9223084D0 (en) * | 1992-11-04 | 1992-12-16 | Imp Cancer Res Tech | Compounds to target cells |
WO1994023751A1 (en) * | 1993-04-14 | 1994-10-27 | Boehringer Mannheim Gmbh | Nucleic acid tranfer peptides and their use for injecting nucleic acids into eucaryotic cells |
US5578475A (en) * | 1993-07-12 | 1996-11-26 | Life Technologies, Inc. | Composition and methods for transfecting eukaryotic cells |
DE4335025A1 (en) * | 1993-10-14 | 1995-04-20 | Boehringer Ingelheim Int | Endosomolytically active particles |
EP0648493A1 (en) * | 1993-10-19 | 1995-04-19 | Tadatsugu Prof. Dr. Taniguchi | A method to reverse the phenotype of transformed cells by the transcription factor IRF-1 |
DE4426429A1 (en) * | 1994-07-26 | 1996-02-01 | Boehringer Ingelheim Int | Method for introducing DNA into higher eukaryotic cells |
DK0699754T3 (en) | 1994-08-12 | 2001-02-26 | Myriad Genetics Inc | Procedure for diagnosing predisposition to breast and ovarian cancer |
DE69521002T3 (en) | 1994-08-12 | 2010-02-25 | The University Of Utah Research Foundation, Salt Lake City | Mutations of the 17q associated ovarian and breast cancer susceptibility gene |
US5846782A (en) * | 1995-11-28 | 1998-12-08 | Genvec, Inc. | Targeting adenovirus with use of constrained peptide motifs |
US6465253B1 (en) | 1994-09-08 | 2002-10-15 | Genvec, Inc. | Vectors and methods for gene transfer to cells |
US5559099A (en) * | 1994-09-08 | 1996-09-24 | Genvec, Inc. | Penton base protein and methods of using same |
US5780009A (en) * | 1995-01-20 | 1998-07-14 | Nexia Biotechnologies, Inc. | Direct gene transfer into the ruminant mammary gland |
US5770442A (en) | 1995-02-21 | 1998-06-23 | Cornell Research Foundation, Inc. | Chimeric adenoviral fiber protein and methods of using same |
US6127525A (en) * | 1995-02-21 | 2000-10-03 | Cornell Research Foundation, Inc. | Chimeric adenoviral coat protein and methods of using same |
AU5979296A (en) * | 1995-06-07 | 1996-12-30 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
US6051429A (en) | 1995-06-07 | 2000-04-18 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
US6783980B2 (en) | 1995-06-15 | 2004-08-31 | Crucell Holland B.V. | Packaging systems for human recombinant adenovirus to be used in gene therapy |
EP0785216B2 (en) | 1995-12-18 | 2006-06-07 | The University of Utah Research Foundation | Chomosome 13-linked breast cancer susceptibility gene BRCA2 |
US5837492A (en) | 1995-12-18 | 1998-11-17 | Myriad Genetics, Inc. | Chromosome 13-linked breast cancer susceptibility gene |
JP2001519646A (en) | 1995-12-22 | 2001-10-23 | ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション | Long QT syndrome gene encoding KVLQT1 and its association with minK |
US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
DE19649645A1 (en) * | 1996-11-29 | 1998-06-04 | Hoechst Ag | Multiple functional ligand system for target cell-specific transfer of nucleotide sequences |
GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
GB9712512D0 (en) | 1997-06-16 | 1997-08-20 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
WO1999008997A1 (en) | 1997-08-13 | 1999-02-25 | Biontex Laboratories Gmbh | Novel lipopolyamines, and the preparation and use thereof |
US6914131B1 (en) | 1998-10-09 | 2005-07-05 | Chiron S.R.L. | Neisserial antigens |
EP1029052B1 (en) | 1997-11-06 | 2010-08-04 | Novartis Vaccines and Diagnostics S.r.l. | Neisserial antigens |
US6780609B1 (en) | 1998-10-23 | 2004-08-24 | Genome Therapeutics Corporation | High bone mass gene of 1.1q13.3 |
DE69941567D1 (en) | 1998-01-14 | 2009-12-03 | Novartis Vaccines & Diagnostic | ANTIGENE FROM NEISSERIA MENINGITIDIS |
WO1999055365A1 (en) | 1998-04-30 | 1999-11-04 | Cornell Research Foundation, Inc. | Adenoviral vectors with tandem fiber proteins |
ES2294629T3 (en) | 1998-05-01 | 2008-04-01 | Novartis Vaccines And Diagnostics, Inc. | ANTIGENS OF NEISSERIA AND COMPOSITIONS. |
US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
WO2000015823A1 (en) | 1998-09-11 | 2000-03-23 | Genvec, Inc. | Alternatively targeted adenovirus |
DE19845420C2 (en) * | 1998-10-02 | 2000-11-16 | Deutsches Krebsforsch | Intercellular spread of recombinant DNA |
JP2002527066A (en) | 1998-10-15 | 2002-08-27 | カイロン コーポレイション | Metastatic breast and colon cancer regulatory genes |
AU772847B2 (en) | 1998-11-12 | 2004-05-06 | Invitrogen Corporation | Transfection reagents |
US6929946B1 (en) | 1998-11-20 | 2005-08-16 | Crucell Holland B.V. | Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells |
JP2003524389A (en) | 1998-12-16 | 2003-08-19 | カイロン コーポレイション | Human cyclin dependent kinase (hPNQALRE) |
ES2397918T3 (en) | 1999-04-30 | 2013-03-12 | Novartis Vaccines And Diagnostics S.R.L. | Neisserial antigens conserved |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
US6492169B1 (en) | 1999-05-18 | 2002-12-10 | Crucell Holland, B.V. | Complementing cell lines |
GB9911683D0 (en) | 1999-05-19 | 1999-07-21 | Chiron Spa | Antigenic peptides |
GB9916529D0 (en) | 1999-07-14 | 1999-09-15 | Chiron Spa | Antigenic peptides |
ES2564463T3 (en) | 1999-10-29 | 2016-03-22 | Glaxosmithkline Biologicals S.A. | Neisserial antigenic peptides |
PT2289545T (en) | 2000-01-17 | 2016-09-06 | Glaxosmithkline Biologicals Sa | Supplemented omv vaccine against meningococcus |
ATE352631T1 (en) | 2000-02-28 | 2007-02-15 | Novartis Vaccines & Diagnostic | HETEROLOGUE EXPRESSION OF NEISSERIA PROTEINS |
EP1950297A2 (en) | 2000-05-31 | 2008-07-30 | Novartis Vaccines and Diagnostics, Inc. | Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers |
US7235233B2 (en) | 2000-09-26 | 2007-06-26 | Crucell Holland B.V. | Serotype 5 adenoviral vectors with chimeric fibers for gene delivery in skeletal muscle cells or myoblasts |
EP2284182A1 (en) | 2000-10-27 | 2011-02-16 | Novartis Vaccines and Diagnostics S.r.l. | Nucleic acids and proteins from streptococcus groups A and B |
US20030188326A1 (en) | 2000-11-03 | 2003-10-02 | Dana Farber Cancer Institute | Methods and compositions for the diagnosis of cancer susceptibilities and defective DNA repair mechanisms and treatment thereof |
WO2002036761A2 (en) | 2000-11-03 | 2002-05-10 | Dana Farber Cancer Institute | Compositions and methods for the diagnosis of cancer |
US6958213B2 (en) | 2000-12-12 | 2005-10-25 | Alligator Bioscience Ab | Method for in vitro molecular evolution of protein function |
US20020086292A1 (en) | 2000-12-22 | 2002-07-04 | Shigeaki Harayama | Synthesis of hybrid polynucleotide molecules using single-stranded polynucleotide molecules |
GB0107658D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Streptococcus pneumoniae |
GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
DE60229363D1 (en) | 2001-03-30 | 2008-11-27 | Ghc Res Dev Corp | MONOCYTE SPECIFIC PARTICULAR ADMINISTRATION VEHICLE |
AUPR546801A0 (en) | 2001-06-05 | 2001-06-28 | Commonwealth Scientific And Industrial Research Organisation | Recombinant antibodies |
EP2335723A1 (en) | 2001-12-12 | 2011-06-22 | Novartis Vaccines and Diagnostics S.r.l. | Immunisation against chlamydia trachomatis |
SI1497438T1 (en) | 2002-04-25 | 2010-03-31 | Crucell Holland Bv | Means and methods for the production of adenovirus vectors |
GB0308198D0 (en) | 2003-04-09 | 2003-05-14 | Chiron Srl | ADP-ribosylating bacterial toxin |
EP1697534B1 (en) | 2003-12-01 | 2010-06-02 | Life Technologies Corporation | Nucleic acid molecules containing recombination sites and methods of using the same |
WO2005067708A2 (en) | 2004-01-14 | 2005-07-28 | Daniolabs Limited | Zebrafish model for autoimmune diseases |
CN104292321A (en) | 2004-03-29 | 2015-01-21 | 株式会社嘉尔药物 | Novel modified galectin 9 protein and use thereof |
WO2006042017A2 (en) | 2004-10-06 | 2006-04-20 | University Of Rochester | Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway |
US8999944B2 (en) | 2005-01-20 | 2015-04-07 | University Of Rochester | Thioredoxin interacting protein (TXNIP) as regulator of vascular function |
WO2007123579A2 (en) | 2005-12-28 | 2007-11-01 | Translational Therapeutics | Translational dysfunction based therapeutics |
EP2007880A2 (en) | 2006-04-07 | 2008-12-31 | Neuro Therapeutics AB | Survival and development of neural cells |
US7723564B2 (en) | 2006-05-10 | 2010-05-25 | Board Of Regents Of The University Of Nebraska | Compositions and methods for modulation of KSR1 and KSR2 interactions |
PL2054431T3 (en) | 2006-06-09 | 2012-07-31 | Novartis Ag | Conformers of bacterial adhesins |
US8673859B2 (en) | 2007-03-20 | 2014-03-18 | New York University | GM-CSF cosmeceutical compositions and methods of use thereof |
US8772238B2 (en) | 2009-03-18 | 2014-07-08 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Use of ixolaris, a tissue factor inhibitor, for the treatment of cancer |
GB0908425D0 (en) | 2009-05-15 | 2009-06-24 | Medical Res Council | Medical use |
CN102596221B (en) | 2009-06-10 | 2019-06-04 | 纽约大学 | The immune targeting of pathological TAU proteins |
GB201012651D0 (en) | 2010-07-28 | 2010-09-15 | Univ Edinburgh | Peptides |
WO2012092341A1 (en) | 2010-12-28 | 2012-07-05 | University Of Rochester | Methods of modifying insulin signaling using biliverdin reductase (bvr) and bvr derived peptides |
PL2753346T3 (en) | 2011-09-07 | 2020-10-19 | Mount Sinai School Of Medicine | Ceramidase and cell differentiation |
EP2908853B1 (en) | 2012-10-21 | 2018-12-05 | University Of Rochester | Thy1 (cd90) as a therapy to control adipose tissue accumulation |
US9822418B2 (en) | 2013-04-22 | 2017-11-21 | Icahn School Of Medicine At Mount Sinai | Mutations in PDGFRB and NOTCH3 as causes of autosomal dominant infantile myofibromatosis |
MX2016014881A (en) | 2014-05-14 | 2017-05-01 | Alex Levitzki Man And Holdings Ltd | Improved polyethyleneimine polyethyleneglycol vectors. |
WO2016011203A1 (en) | 2014-07-15 | 2016-01-21 | Life Technologies Corporation | Compositions with lipid aggregates and methods for efficient delivery of molecules to cells |
EP3371211A4 (en) | 2015-11-04 | 2019-08-21 | Icahn School of Medicine at Mount Sinai | Methods of treating tumors and cancer, and identifying candidate subjects for such treatment |
US11246868B2 (en) | 2016-04-26 | 2022-02-15 | Icahn School Of Medicine At Mount Sinai | Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment |
CN111413499B (en) * | 2020-04-17 | 2023-06-27 | 中国兽医药品监察所 | Indirect immunofluorescence kit for detecting avian adenovirus I group |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5354844A (en) * | 1989-03-16 | 1994-10-11 | Boehringer Ingelheim International Gmbh | Protein-polycation conjugates |
WO1991004753A1 (en) * | 1989-10-02 | 1991-04-18 | Cetus Corporation | Conjugates of antisense oligonucleotides and therapeutic uses thereof |
-
1992
- 1992-09-04 IL IL103059A patent/IL103059A0/en unknown
- 1992-09-10 NZ NZ244291A patent/NZ244291A/en unknown
- 1992-09-14 MX MX9205226A patent/MX9205226A/en not_active IP Right Cessation
- 1992-09-21 TW TW081107455A patent/TW249247B/zh active
- 1992-09-28 HU HU9400899A patent/HUT71322A/en unknown
- 1992-09-28 JP JP50658993A patent/JP3479298B2/en not_active Expired - Fee Related
- 1992-09-28 DE DE59209778T patent/DE59209778D1/en not_active Expired - Fee Related
- 1992-09-28 EP EP92116577A patent/EP0535576A1/en active Pending
- 1992-09-28 CA CA002114800A patent/CA2114800A1/en not_active Abandoned
- 1992-09-28 AT AT92919852T patent/ATE187497T1/en not_active IP Right Cessation
- 1992-09-28 EP EP92919852A patent/EP0606280B1/en not_active Expired - Lifetime
- 1992-09-28 WO PCT/EP1992/002231 patent/WO1993007282A1/en active IP Right Grant
- 1992-09-28 CN CN92110625A patent/CN1071457A/en active Pending
- 1992-09-28 AU AU25932/92A patent/AU669335B2/en not_active Ceased
-
1994
- 1994-03-29 NO NO941155A patent/NO941155D0/en unknown
- 1994-03-30 FI FI941473A patent/FI941473A0/en unknown
-
1995
- 1995-06-30 HU HU95P/P00695P patent/HU211902A9/en unknown
Also Published As
Publication number | Publication date |
---|---|
HU211902A9 (en) | 1996-01-29 |
NO941155L (en) | 1994-03-29 |
HUT71322A (en) | 1995-11-28 |
FI941473A (en) | 1994-03-30 |
NZ244291A (en) | 1995-07-26 |
AU2593292A (en) | 1993-05-03 |
JP3479298B2 (en) | 2003-12-15 |
FI941473A0 (en) | 1994-03-30 |
NO941155D0 (en) | 1994-03-29 |
EP0606280B1 (en) | 1999-12-08 |
ATE187497T1 (en) | 1999-12-15 |
MX9205226A (en) | 1993-03-01 |
DE59209778D1 (en) | 2000-01-13 |
WO1993007282A1 (en) | 1993-04-15 |
CA2114800A1 (en) | 1993-04-15 |
HU9400899D0 (en) | 1994-06-28 |
TW249247B (en) | 1995-06-11 |
JPH07500009A (en) | 1995-01-05 |
CN1071457A (en) | 1993-04-28 |
EP0606280A1 (en) | 1994-07-20 |
AU669335B2 (en) | 1996-06-06 |
EP0535576A1 (en) | 1993-04-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL103059A0 (en) | Conjugates for introducing nucleic acid into higher eucaryotic cells | |
IL103171A0 (en) | Composition for introducing nucleic acid complexes into higher eucaryotic cells | |
DE59207189D1 (en) | NEW COMPLEXES CONTAINED BY ENDOCYTOSIS IN HIGHER EUKARYOTIC CELLS, NUCLEIC ACID | |
ATE195144T1 (en) | NEW PROTEIN POLYCATION CONJUGATES | |
GB2286593A (en) | Virus with modified binding moiety specific for the target cells | |
PT1244805E (en) | DISTRIBUTION COMPLEXES OF CATIONIC PROTEIN-LIPID-NUCLEIC ACID OF THE VIRAL NUCLEUS | |
US5922859A (en) | Complexes containing nucleic acid which can be taken-up by endocytosis into higher eukaryotic cells | |
WO1994006923A1 (en) | Modification of a virus to redirect infectivity and enhance targeted delivery of polynucleotides to cells | |
Kichler et al. | Efficient gene delivery with neutral complexes of lipospermine and thiol-reactive phospholipids | |
GR3036634T3 (en) | Novel protein polycation conjugates. | |
Loyter et al. | Fusion-mediated injection of SV40-DNA: introduction of SV40-DNA into tissue culture cells by the use of DNA-loaded reconstituted Sendai virus envelopes | |
CA2189051A1 (en) | Composition for delivery of toxic radioisotopes to the cell nucleus and use | |
AU8818398A (en) | Conjugates of dna interacting groups with steroid hormones for use as nucleic acid transfection agent | |
WO1992019281A3 (en) | New conjugates, consisting of a glycoprotein and a nucleic acid-binding substance | |
AU3354795A (en) | Gene-Containing Compositions | |
YU87292A (en) | COMPOSITION FOR INPUTING NUCLEIC ACID COMPLEXES IN MORE EUKARIOTIC CELLS |